NCT04051827View on ClinicalTrials.gov

Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 23, 2019

Primary Completion Date

December 17, 2020

Study Completion Date

December 7, 2021

Conditions
Carcinoma, Non-Small-Cell LungLung Neoplasms
Interventions
DRUG

Midazolam

Midazolam Oral Solution and Midazolam Intravenous Infusion.

DRUG

TAK-788

TAK-788 Oral Capsules.

Trial Locations (8)

2065

Royal North Shore Hospital, St Leonards

3004

Nucleus Network, Melbourne

3199

Peninsula and Southeast Oncology, Frankston

5042

Flinders Medical Centre, Bedford Park

119074

The National University Cancer Institute - Singapore, Singapore

188770

Raffles Hospital, Singapore

1066 CX

Netherlands Cancer Institute, Amsterdam

9700 RB

Universitair Medisch Centrum Groningen, Groningen

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY